Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:ATCCode |
gptkb:J07BX08
|
| gptkbp:brand |
gptkb:Arexvy
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:contains |
gptkb:AS01E_adjuvant
gptkb:RSV_prefusion_F_glycoprotein_antigen |
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| https://www.w3.org/2000/01/rdf-schema#label |
Arexvy
|
| gptkbp:indication |
adults 60 years of age and older
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
fatigue headache joint pain muscle pain injection site pain |
| gptkbp:usedFor |
prevention of respiratory syncytial virus (RSV) infection
|
| gptkbp:bfsParent |
gptkb:RSV
|
| gptkbp:bfsLayer |
6
|